Incyteの空売り状況は、投資家がIncyteの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Incyte (NASDAQ:INCY) 株価情報, 空売り情報

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Corp

The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
&nbsp;Niktimvo is the first and only FDA-approved prescription treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis.

News

INCY

SNDX

Incyte, Syndax Announce FDA Approval Of Niktimvo 9 mg And 22 mg Vial Sizes; US Launch Expected In Early February

JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Market Perform to Market Perform.

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Perform on Incyteto Market Perform

On Monday, Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) presented at the JP Morgan <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42943900/incyte-highlights-commercial-growth-clinical-progress-and-2025-milestones-at-the-43rd-annual-j-p-m" rel="noreferrer noopener">Healthcare Conference</a>.
Incyte outlined a pivotal year ahead during its JPM presentation, describing 2025 as a &#8220;year of defining catalysts.&#8221;
The company anticipates four potential drug launches, pivotal trial readouts, and advancements in its pipeline.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42069374/incytes-750-million-escient-deal-faces-setback-with-toxicology-issues-in-two-investigational-drugs-analyst-flags-challenges" rel="noreferrer noopener">Incyte&#8217;s $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges</a>
Incyte estimates the anticipated four launches could contribute approximately $1 billion in incremental revenues by 2029.
The company is also <a target="_blank" href="https://investor.incyte.com/static-files/f0037aa1-59bf-467c-a2cd-59fff2c6393c" rel="noreferrer noopener">preparing</a> for a transformative year, with highlights including four pivotal trial results, seven proof-of-concept data readouts, and at least three Phase 3 study initiations.
Planned 2025 Drug Launches
<ul>
<li>Among the near-term launches are Niktimvo, approved for third-line chronic graft-versus-host disease, expected to hit the U.S. market in the first quarter of 2025.</li>
<li>Additional launches include ruxolitinib cream for pediatric atopic dermatitis, tafasitamab for follicular lymphoma, and retifanlimab for squamous cell anal carcinoma, all pending approvals in the second half of the year.</li>
</ul>
Strategic Growth Toward 2030
<ul>
<li>Incyte&#8217;s long-term vision includes more than ten impactful product launches by 2030.</li>
<li>Key candidates include povorcitinib, which is being developed for multiple indications and has significant market opportunities.</li>
<li>For moderate-to-severe hidradenitis suppurativa alone, Phase 3 data is expected in the first half of 2025, targeting a $3 billion U.S. market with over 300,000 affected patients.</li>
<li>The drug is also being studied for extensive nonsegmental vitiligo and prurigo nodularis, which are underserved conditions with high market potential. Phase 3 data for these indications are expected in 2026, and combined market opportunities will exceed $4 billion.</li>
</ul>
Additional Promising Assets
<ul>
<li>Incyte highlighted the potential of its mCALR program for myelofibrosis and Essential thrombocythemia with CALR mutation. Proof-of-concept data are anticipated in 2025</li>
<li>A CDK2 inhibitor aims to address unmet needs in ovarian cancer. It is expected to enter a pivotal trial in 2025.</li>
</ul>
Incyte&nbsp;reported&nbsp;third-quarter revenue&nbsp;of $1.14 billion, up 24% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41637452/incytes-jakafi-demand-is-strong-analyst-upgrades-stock" rel="noreferrer noopener">consensus of $1.08 billion</a>.
Jakafi&nbsp;(ruxolitinib) net product revenues increased to&nbsp;$741.18 million, up 16% year over year, primarily due to a 10% increase in total demand.
Price Action: INCY stock closed at $72.37 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42958251/on-semi-sees-utilization-cuts-as-ev-demand-softens-analyst-warns" target="_blank" rel="noreferrer noopener">ON Semi Sees Utilization Cuts As EV Demand Softens, Analyst Warns</a></li>
</ul>

Biotech

Large Cap

Health Care

General

Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Neutral to Neutral.

Cantor Fitzgerald Reiterates Neutral on Incyteto Neutral

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Incyte, presenting an average target of $73.27, a high estimate of $97.00, and a low estimate of $52.00. This current average reflects an increase of 7.53% from the previous average price target of $68.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1734642065_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Incyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$74.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$68.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Incyte. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Incyte's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>Discovering Incyte: A Closer Look</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>A Deep Dive into Incyte's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.81%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.45%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.2%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Incyte adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Incyte In The Eyes Of 15 Experts

Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Equal-Weight and raises the price target from $68 to $70.

Price Target

Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $70

Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 inMIND Trial Endpoints; U.S. sBLA Filing Planned By Year-End 2024

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announced results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz&#xAE;), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer (NSCLC) not harboring a driver mutation. These data were featured today in a mini oral presentation at the European Society for Medical Oncology (ESMO) Asia Congress 2024, held in Singapore and virtually.
&nbsp;
— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS) and all secondary endpoints in patients with previously untreated metastatic non-small cell lung cancer (NSCLC)
— Data presented at the European Society for Medical Oncology (ESMO) Asia Congress 2024 support the planned 2025 filing of a supplemental Biologics License Application (sBLA) in the U.S. for retifanlimab in NSCLC

Incyte Announced Results From Phase 3 Trial Evaluating Retifanlimab In Combination With Platinum-based Chemotherapy In Patients With Non-small Cell Lung Cancer At ESMO Congress; Said Phase 3 POD1UM-304  Trial Met Primary Endpoint Of Overall Survival And All Secondary Endpoints In Patients With Previously Untreated Metastatic NSCLC

Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 inMIND Results And Virtual Analyst Event On December 12

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol start="1">
<li>Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) tumbled 17.83% after the company reported the third-quarter earnings miss, and analysts slashed the <a href="https://www.benzinga.com/node/42117500" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) plummeted 12.22% after the company reported <a href="https://www.benzinga.com/node/42111158" target="_blank" rel="noreferrer noopener">worse-than-expected financial results</a>. Analysts cut <a href="https://www.benzinga.com/quote/pdd/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>ZTO Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) stock fell 8.50% after the company reported third-quarter results and cut its FY24 <a href="https://www.benzinga.com/node/42076268" target="_blank" rel="noreferrer noopener">guidance for parcel volume</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock dipped 7.54% after Raymond James downgraded the stock <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">from Strong Buy to Outperform</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) fell 7.34% after Berkshire Hathaway <a href="https://www.benzinga.com/node/42013172">cut its position</a> in the stock.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) declined 6.94% after the company <a href="https://www.benzinga.com/node/42123997" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Several analysts revised <a href="https://www.benzinga.com/quote/intu/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecasts on the stock</a>.</li>
<li>Nokia Corporation NYSE: NOK) stock decreased 6.28%. The company secured a multi-year, multi-billion USD contract extension <a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener">with </a><a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener">Bharti Airtel</a><a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener"> in India</a>.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares were down 6.16%. The company plans to issue U.S. dollars and Chinese yuan bonds to raise capital, repay existing debt, and support <a href="https://www.benzinga.com/node/42032495" target="_blank" rel="noreferrer noopener">an ongoing stock buyback initiative</a>.</li>
<li>Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) stock dipped 5.60%.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock declined 5.47% after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic does not <a href="https://www.benzinga.com/node/42070590" target="_blank" rel="noreferrer noopener">support further development</a>.</li>
</ol>
Photo via Shutterstock

Movers

Trading Ideas

BABA

INTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

ULTA

Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock moved upwards by 26.4% to $3.26 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 19.1% to $3.74. The company's market cap stands at $267.1 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares rose 15.74% to $10.0. The market value of their outstanding shares is at $544.0 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares rose 15.41% to $0.42. The company's market cap stands at $1.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 15.32% to $1.43. The company's market cap stands at $54.0 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 14.36% to $1.1. The company's market cap stands at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 16.3% to $0.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock fell 12.31% to $67.5. The market value of their outstanding shares is at $13.0 billion. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) stock declined by 10.78% to $5.38. The market value of their outstanding shares is at $693.0 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 10.42% to $8.26. The company's market cap stands at $5.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 9.8% to $0.26. The company's market cap stands at $1.4 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) stock decreased by 9.26% to $25.0. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ALKS

ALMS

APLM

CTKB

FRES

GCTK

GRFS

HCWB

SNOA

TFFP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
The Dow traded down 0.03% to 43,374.79 while the NASDAQ rose 1.03% to 18,985.21. The S&amp;P 500 also rose, gaining, 0.49% to 5,922.41.
Check This Out: <a href="https://www.benzinga.com/24/11/42059659/this-apollo-global-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Leading and Lagging Sectors Information technology shares rose by 0.6% on Tuesday.
In trading on Tuesday, materials shares fell by 0.6%.
Top Headline
Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported better-than-expected results for its second quarter and raise its outlook.
The company posted second-quarter 2025 sales of $8.40 billion, beating the consensus of $8.27 billion. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.
Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up from the prior 4.5%-5%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%. Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares shot up 29% to $27.84 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Shares of PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) got a boost, surging 172% to $1.4600. The company announced a 1-for-4 reverse stock split.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares were also up, gaining 30% to $3.30. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares dropped 12% to $1.06. NWTN received Nasdaq staff delisting determination for non-compliance with Listing Rule 5250(c)(1).</li>
<li>Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) were down 13% to $66.74 after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) was down, falling 11% to $6.77 after the company received a Nasdaq delisting notice due to its public reports rule.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.12 while gold traded up 0.7% at $2,632.40.
Silver traded up 0.3% to $31.305 on Tuesday, while copper rose 0.6% to $4.1435.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.45%, Germany's DAX fell 0.67% and France's CAC 40 fell 0.67%. Spain's IBEX 35 Index fell 0.74%, while London's FTSE 100 fell 0.13%.
Hourly labor costs in the Eurozone rose by 4.6% year-over-year in the third quarter compared to a revised 5% gain in the prior quarter. Annual inflation in the Eurozone rose to 2% in October from 1.7% in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.51%, Hong Kong's Hang Seng Index gaining 0.44%, China's Shanghai Composite Index gaining 0.67%&nbsp; and India's BSE Sensex gaining 0.31%.
Malaysia&#8217;s trade surplus narrowed to MYR 12.0 billion in October from MYR 13.0 billion in the year-ago month.
Economics
<ul>
<li>Housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month.</li>
<li>U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42060404/nvidia-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-tuesday-2">Nvidia To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CDRO

NWTN

PRFX

SMCI

TRNR

Gold Moves Higher; Medtronic Posts Upbeat Results

Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the <a href="https://www.benzinga.com/topic/russia">ongoing Russia-Ukraine conflict.</a>
Ukraine launched its first U.S.-made missile strike on a Russian city, while Russian President Vladimir Putin adjusted the nation's nuclear doctrine to broaden scenarios for a potential response. Yet, Russian Foreign Minister Sergei Lavrov sought to assuage fears of a nuclear escalation, stating that a nuclear war is not something Russia is considering.
Amid the geopolitical noise, investors remained focused on corporate earnings. Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), often regarded as a bellwether of consumer health, surpassed expectations for the recent quarter. The retailer&#8217;s stock surged 4%, hitting fresh all-time highs and boosting market sentiment.
At midday, both the S&amp;P 500 and Nasdaq 100 posted marginal gains, while blue-chip stocks showed a slight deceleration and small caps held steady.
In fixed income, longer-dated bond yields dipped, with the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) climbing 0.5%. The U.S. dollar gained 0.1%, attempting to rebound after two consecutive sessions of losses.
Geopolitical risks lifted demand for commodities, with gold and oil rebounding 0.8% and 0.5%, respectively. Natural gas prices – as closely tracked by the United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) – extended the rally, adding 2.6% after a 5.3% jump on Monday and hitting the highest levels since June. 
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continued to display extraordinary strength, with the cryptocurrency breaking to a new all-time high of $93,931, underscoring robust market interest despite broader macro uncertainties.
<h2 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,610.47</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,907.68</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,309.75</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,316.79</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 13:10 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.2% to $589.41.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.3% to $433.10.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.4% higher to $502.08.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.3% to $229.50.</li>
<li>The&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, rising 0.5%. The&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.7%.</li>
</ul>
<h2 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h2>
<ul>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) surged 22% after appointing BDO US as its auditor and submitting a compliance plan to Nasdaq, signaling a proactive effort to address delisting concerns. The news bolstered investor confidence in the company&#8217;s governance and market stability.</li>
<li>United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) climbed 3.5%, reaching its highest level since December 2019, following a bullish call from TD Owen, which raised the stock's price target from $100 to $110.</li>
<li>Incyte Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NYSE">INCY</a>) plummeted over 14% after announcing that data from its Phase 2 clinical study failed to support further development, disappointing investors hoping for progress in its pipeline.</li>
<li>Valvoline Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) dropped 8% in reaction to a weaker-than-expected earnings report, as the market digested concerns over the company&#8217;s growth trajectory and profitability.</li>
<li>Vertive Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) rallied 11.7% in reaction to price target raises from investment banks such as Deustsce Bank and Oppenheimer.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42069891/sp-500-to-reach-6500-by-end-of-2025-analysts-predict-could-it-spark-ma-revival">S&amp;P 500 To Reach 6,500 By End Of 2025, Analysts Predict: Could It Spark M&amp;A Revival?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Bonds

Specialty ETFs

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?

Incyte Shares Resume Trade

<a href="https://x.com/MarkKleinmanSky/status/1858942117827018868" title="https://x.com/MarkKleinmanSky/status/1858942117827018868">https://x.com/MarkKleinmanSky/status/1858942117827018868</a>

Watching Incyte; Sky News City Editor Mark Kleinman Posts On X "Merck Is The Latest Industry Giant To Be Linked To A Takeover Bid For Incyte, With Which It Collaborates On Several Drug Development Projects."

Incyte Shares Halted On Circuit Breaker To The Upside, Stock Now Down - 9.67%

Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not <a href="https://www.benzinga.com//node/42069374">support further development</a>. 
The Details: The company&#8217;s Phase 2 study evaluated MRGPRX4 in cholestatic pruritus, however, the data does not warrant further development.
In addition, Incyte announced that the company is pausing enrollment in its ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria. The decision was made after discovering some issues in early testing. 
The company will work with the U.S. Food and Drug Administration to determine next steps.
How To Buy Incyte Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Incyte's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/government/regulations/24/11/42045345/us-stocks-rebound-tesla-rallies-bitcoin-soars-above-92000-whats-driving-markets-monday">US Stocks Rebound, Tesla Rallies, Bitcoin Soars Above $92,000: What&#8217;s Driving Markets Monday?</a>
INCY Price Action: At the time of writing, Incyte shares are trading 13.9% lower at $66.27, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Michal Jarmoluk from Pixabay

What's Going On With Incyte Shares Tuesday?

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Tuesday.
Shares of AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ACM/earnings">fourth-quarter results</a>.
The company reported better-than-expected earnings for its fourth quarter. The company&#8217;s quarterly earnings came in at $1.27 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $4.11 billion versus the analyst consensus estimate of $4.14 billion.
Aecom shares declined 3.3% to $105.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Hanmi Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) shares tumbled 20.9% to $20.24 in pre-market trading.</li>
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) fell 20.7% to $16.96 in pre-market trading.</li>
<li>Flushing Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIC#NASDAQ">FFIC</a>) declined 12.2% to $15.25 in pre-market trading.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 10.3% to $68.98 in today's pre-market trading after the company issued an update on early Phase MRGPRX2 and MRGPRX4 programs.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined 9.1% to $8.38 in pre-market trading.</li>
<li>Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) shares fell 7.3% to $8.37 in pre-market trading after jumping over 20% on Monday.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 5.8% to $30.86 in pre-market trading after jumping around 17% on Monday.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) shares fell 5.8% to $1.61 in pre-market trading. Globalstar announced its board of directors authorized a reverse stock split of its common stock.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Pre-Market Outlook

FFIC

GRDN

GSAT

HAFC

NEXN

Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

On Monday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42049159/incyte-provides-update-on-early-phase-mrgprx2-and-mrgprx4-programs" rel="noreferrer noopener">spontaneous urticaria (CSU)</a>.
The decision was made following the observation of certain in vivo preclinical toxicology findings.
These data have been shared with the FDA, and Incyte will work closely with the FDA to determine the next steps.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41637452/incytes-jakafi-demand-is-strong-analyst-upgrades-stock" rel="noreferrer noopener">Incyte&#8217;s Jakafi Demand Is Strong, Analyst Upgrades Stock</a>
Enrollment in the other INCB000262 proof-of-concept studies is complete. Data from all clinical studies will help inform its future development and guide the potential development of backup molecules.
In addition, data from the Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus (CP) does not support further development.
The company added the investigational drugs via the Escient Pharmaceuticals deal <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38388366/incyte-should-consider-significant-stock-buyback-and-prioritize-r-d-analyst-recomme" rel="noreferrer noopener">for $750 million</a>.
William Blair says the &#8216;update is clearly disappointing&#8217; as the proof-of-concept data across all three indications was anticipated in the first quarter of 2025.
The analyst has not included estimates for the molecule in the model yet. However, William Blair previously projected it could launch in 2029 and bring substantial sales for Incyte in the 2030s, as it&#8217;s being tested for major market opportunities with the potential to become a blockbuster.
&#8220;Although ‘547 was not the focus of the Escient acquisition, it is clearly negative to also see the discontinuation of the other clinical-stage program associated with the acquisition,&#8221; the analyst adds.
William Blair writes that before more information is released about the toxicology findings and next steps for the ‘262 program, investors are likely to focus on other key pipeline updates expected in 2025.
These include Phase 3 results for povorcitinib in hidradenitis suppurativa, due in early 2025, and initial data on mutant-specific inhibitors (mCALR and JAK2V617F) for myeloproliferative neoplasms later in the year. These developments could significantly impact Incyte&#8217;s long-term outlook.
Price Action: INCY stock fell 11.35% at $68.28 during premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42054284/whats-going-on-with-mullen-automotive-stock-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Mullen Automotive Stock Monday?</a></li>
</ul>

Analyst Color

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining by around 100 points on Tuesday.
The Dow traded down 0.34% to 43,244.07 while the NASDAQ rose 0.53% to 18,892.31. The S&amp;P 500 also rose, gaining, 0.14% to 5,902.02.
Check This Out: <a href="https://www.benzinga.com/24/11/42059659/this-apollo-global-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Leading and Lagging Sectors Information technology shares rose by 0.2% on Tuesday.
In trading on Tuesday, materials shares fell by 0.9%.
Top Headline
Lowe's Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) posted better-than-expected earnings for its third quarter on Tuesday.
The company reported third-quarter adjusted earnings per share of $2.89 beating the street view of $2.82. Quarterly sales of $20.170 billion outpaced the analyst consensus estimate of $19.424 billion.
Lowe's has revised its fiscal year 2024 outlook for its adjusted earnings per share (EPS) guidance from a range of $11.70 – $11.90 to a range of $11.80 – $11.90, compared with the consensus estimate of $11.85. Additionally, the company raised its sales forecast from a range of $82.70 billion – $83.20 billion to a new range of $83.00 billion – $83.50 billion, compared with the consensus estimate of $83.05 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares shot up 28% to $27.54 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Shares of PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) got a boost, surging 195% to $1.5999. The company announced a 1-for-4 reverse stock split.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares were also up, gaining 48% to $3.75. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares dropped 12% to $1.06. NWTN received Nasdaq staff delisting determination for non-compliance with Listing Rule 5250(c)(1).</li>
<li>Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) were down 11% to $68.17 after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) was down, falling 9% to $6.93 after the company received a Nasdaq delisting notice due to its public reports rule.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $69.58 while gold traded up 0.6% at $2,630.60.
Silver traded up 0.1% to $31.255 on Tuesday, while copper fell 0.3% to $4.1080.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.91%, Germany's DAX fell 1.28% and France's CAC 40 fell 1.26%. Spain's IBEX 35 Index fell 1.47%, while London's FTSE 100 fell 0.36%.
Hourly labor costs in the Eurozone rose by 4.6% year-over-year in the third quarter compared to a revised 5% gain in the prior quarter. Annual inflation in the Eurozone rose to 2% in October from 1.7% in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.51%, Hong Kong's Hang Seng Index gaining 0.44%, China's Shanghai Composite Index gaining 0.67%&nbsp; and India's BSE Sensex gaining 0.31%.
Malaysia&#8217;s trade surplus narrowed to MYR 12.0 billion in October from MYR 13.0 billion in the year-ago month.
Economics
<ul>
<li>Housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month.</li>
<li>U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42060404/nvidia-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-tuesday-2">Nvidia To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Nasdaq Gains 100 Points; Lowe's Earnings Beat Views

Notable gainers among liquid option names this morning include Moderna (MRNA) $47.27 +4.70, Enphase Energy (ENPH) $76.27 +4.89, Micron (MU) $105.88...

Early notable gainers among liquid option names on January 7th

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Incyte (INCY – Research Report), with a pric...

Incyte (INCY) Receives a Hold from Truist Financial

Incyte ( ($INCY) ) just unveiled an update. Incyte Corporation announced that Barry P. Flannelly, Executive Vice President and General Manager, Nor...

Incyte Announces Retirement of Executive VP Barry Flannelly

Incyte: Multiple Drug Launches Bode Well For Future Growth

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

JMP Securities analyst Reni Benjamin has reiterated their neutral stance on INCY stock, giving a Hold rating on January 8. Reni Benjamin gave his r...

Incyte Stock: Hold Rating Amid Patent Cliff Concerns and Awaited Clinical Milestones

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Sell rating on Incyte (INCY – Research Report), with a price target of...

Incyte's Strategic Challenges: Navigating Post-Jakafi Growth Gap and Limited Business Development Capacity

In a report released today, Kelly Shi from Jefferies maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $84.00. The...

Jefferies Remains a Buy on Incyte (INCY)

Incyte (INCY) and Syndax (SNDX) announced that the FDA has approved Niktimvo in 9 mg and 22 mg vial sizes. The companies expect product to be avail...

Incyte, Syndax announce FDA approval for Niktimvo vial sizes

Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials

ABBV

AMGN

AZNCF

BNTX

ENPH

FBCG

GILD

GLAXF

IOVA

LGND

MRNA

NVSEF

REGN

SMMT

TSVT

Press Releases

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

Comments

Incyte

空売り

Incyte (NASDAQ:INCY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル